DE2327636A1 - Pharmazeutisches praeparat - Google Patents
Pharmazeutisches praeparatInfo
- Publication number
- DE2327636A1 DE2327636A1 DE19732327636 DE2327636A DE2327636A1 DE 2327636 A1 DE2327636 A1 DE 2327636A1 DE 19732327636 DE19732327636 DE 19732327636 DE 2327636 A DE2327636 A DE 2327636A DE 2327636 A1 DE2327636 A1 DE 2327636A1
- Authority
- DE
- Germany
- Prior art keywords
- seryl
- hydrazine
- pharmaceutically acceptable
- trihydroxybenzyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims description 25
- 229960002888 oxitriptan Drugs 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- -1 DL-Seryl Chemical group 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- KGZOXBILQUWCPB-UHFFFAOYSA-N 2-amino-3-hydroxy-n-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide Chemical compound OCC(N)C(=O)N(N)CC1=CC=C(O)C(O)=C1O KGZOXBILQUWCPB-UHFFFAOYSA-N 0.000 claims description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000001802 infusion Methods 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 210000001147 pulmonary artery Anatomy 0.000 description 3
- BARUGVIPWPSKOJ-UHFFFAOYSA-N 4-(hydrazinylmethyl)benzene-1,2,3-triol Chemical compound NNCC1=CC=C(O)C(O)=C1O BARUGVIPWPSKOJ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- ULFCBIUXQQYDEI-UHFFFAOYSA-N benserazide hydrochloride Chemical compound Cl.OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O ULFCBIUXQQYDEI-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940077481 dl- 5-hydroxytryptophan Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940043673 aluminum hydroxide / calcium carbonate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH984672 | 1972-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2327636A1 true DE2327636A1 (de) | 1974-01-17 |
Family
ID=4356299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732327636 Pending DE2327636A1 (de) | 1972-06-30 | 1973-05-30 | Pharmazeutisches praeparat |
Country Status (18)
| Country | Link |
|---|---|
| AT (1) | AT338412B (enExample) |
| AU (1) | AU476456B2 (enExample) |
| BE (1) | BE801645A (enExample) |
| CA (1) | CA1015272A (enExample) |
| DD (1) | DD107592A5 (enExample) |
| DE (1) | DE2327636A1 (enExample) |
| ES (1) | ES416383A1 (enExample) |
| FR (1) | FR2190453B1 (enExample) |
| GB (1) | GB1369189A (enExample) |
| HU (1) | HU167292B (enExample) |
| IE (1) | IE37833B1 (enExample) |
| IL (1) | IL42317A (enExample) |
| LU (1) | LU67898A1 (enExample) |
| NL (1) | NL7308435A (enExample) |
| PH (1) | PH9584A (enExample) |
| SE (1) | SE407744B (enExample) |
| SU (1) | SU533323A3 (enExample) |
| ZA (1) | ZA733284B (enExample) |
-
1973
- 1973-05-15 ZA ZA733284A patent/ZA733284B/xx unknown
- 1973-05-18 AU AU55897/73A patent/AU476456B2/en not_active Expired
- 1973-05-21 IL IL42317A patent/IL42317A/en unknown
- 1973-05-30 DE DE19732327636 patent/DE2327636A1/de active Pending
- 1973-06-18 NL NL7308435A patent/NL7308435A/xx not_active Application Discontinuation
- 1973-06-22 IE IE1034/72A patent/IE37833B1/xx unknown
- 1973-06-27 FR FR7323456A patent/FR2190453B1/fr not_active Expired
- 1973-06-28 ES ES416383A patent/ES416383A1/es not_active Expired
- 1973-06-28 PH PH14782*UA patent/PH9584A/en unknown
- 1973-06-28 SU SU1940152A patent/SU533323A3/ru active
- 1973-06-28 LU LU67898A patent/LU67898A1/xx unknown
- 1973-06-28 CA CA175,140A patent/CA1015272A/en not_active Expired
- 1973-06-29 HU HUHO1588A patent/HU167292B/hu unknown
- 1973-06-29 BE BE132885A patent/BE801645A/xx unknown
- 1973-06-29 GB GB3107173A patent/GB1369189A/en not_active Expired
- 1973-06-29 DD DD171943A patent/DD107592A5/xx unknown
- 1973-06-29 AT AT574273A patent/AT338412B/de not_active IP Right Cessation
- 1973-06-29 SE SE7309254A patent/SE407744B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU167292B (enExample) | 1975-09-27 |
| AU476456B2 (en) | 1976-09-23 |
| SU533323A3 (ru) | 1976-10-25 |
| SE407744B (sv) | 1979-04-23 |
| LU67898A1 (enExample) | 1975-04-11 |
| PH9584A (en) | 1976-01-19 |
| IE37833B1 (en) | 1977-10-26 |
| ATA574273A (de) | 1976-12-15 |
| DD107592A5 (enExample) | 1974-08-12 |
| AU5589773A (en) | 1974-11-21 |
| IE37833L (en) | 1973-12-30 |
| IL42317A (en) | 1976-04-30 |
| IL42317A0 (en) | 1973-07-30 |
| FR2190453A1 (enExample) | 1974-02-01 |
| GB1369189A (en) | 1974-10-02 |
| BE801645A (fr) | 1974-01-02 |
| AT338412B (de) | 1977-08-25 |
| FR2190453B1 (enExample) | 1976-04-09 |
| CA1015272A (en) | 1977-08-09 |
| NL7308435A (enExample) | 1974-01-02 |
| ZA733284B (en) | 1974-03-27 |
| ES416383A1 (es) | 1976-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69710390T2 (de) | Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren | |
| DE3586545T2 (de) | Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen. | |
| DE2856393C2 (de) | Arzneimittel zur Behandlung von Morbus Parkinson | |
| DE4037708A1 (de) | Appetitzuegler und verfahren zu seiner anwendung | |
| DE19938825A1 (de) | Wirkstoffkombination mit Clonidin | |
| DE69328792T2 (de) | Behandlung von migräne | |
| EP0224810B1 (de) | Antihypertensives Kombinationspräparat | |
| EP0007597B1 (de) | N-Niedrigalkylglycinamide und Sarkosinanhydrid sowie in Kombination mit bekannten tumorhemmenden Verbindungen vorliegendes Sarkosin zur Anwendung bei der Heilung von Tumoren sowie dieselben enthaltendes Mittel und Verfahren zu dessen Herstellung | |
| DE2359128A1 (de) | Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen | |
| EP0132595B1 (de) | Tokolytisches Mittel | |
| DE3011274C2 (de) | Pharmazeutisches Präparat mit Strahlenschutzwirkung | |
| DE2327636A1 (de) | Pharmazeutisches praeparat | |
| DE2513597B2 (de) | L-5-hydroxytryptophan-l-glutamatmonohydrat, verfahren zu seiner herstellung und arzneimittel | |
| DE2128730A1 (de) | Mittel zur Kompensierung eines Dopaminmangels im Gehirn | |
| DE2525064A1 (de) | Arzneimittel und verfahren zu seiner herstellung | |
| DE1792271C3 (de) | Blutdrucksenkendes Arzneimittel | |
| DE2823267C2 (enExample) | ||
| DE1963223A1 (de) | Mittel zur Behandlung von Virusinfektionen | |
| DE4217396A1 (de) | Metrifonat enthaltendes Arzneimittel | |
| DE2532180C2 (de) | Verwendung von Etozolin bei der Bekämpfung der Hypertonie | |
| DE2810051A1 (de) | Zubereitung fuer die behandlung von asthma | |
| DE1806400A1 (de) | Pharmazeutisches Produkt,insbesondere injizierbares Lakalanaesthetikum | |
| DE2254018A1 (de) | Neue pharmazeutische praeparate | |
| DE2109657C3 (de) | DL-m-Tyrosinester und L-m-Tyrosinester, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE3006575A1 (de) | Mittel zur behandlung der fettleibigkeit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHA | Expiration of time for request for examination |